Beta Bionics discloses securities class action over iLet statements

A purported stockholder has filed a securities class action against Beta Bionics, Inc. (Nasdaq: BBNX) and certain of its executive officers, according to the company's 10-Q for the quarter ended September 30, 2026, filed October 27. The case is captioned Holtzman vs. Beta Bionics, Inc. et al., Case No. 8:26-cv-2612-JWH (KESx), in the U.S. District Court for the Central District of California. The filing says it was brought in September 2026 and gives no day.

The defendants are Beta Bionics and "certain of our executive officers." The 10-Q does not name the officers or the plaintiff's law firm, and it names no director, underwriter or other defendant.

The allegations

The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5, by making material misstatements or omissions about the safety, efficacy and commercial success of the iLet, the company's insulin delivery device. These are allegations. On behalf of the putative class, the plaintiff seeks unspecified damages, pre- and post-judgment interest, attorneys' fees, expert fees and costs, and class certification. The 10-Q gives no class period.

Beta Bionics says it intends to vigorously defend against the claims. It says any potential loss is not currently probable nor estimable, so it has booked nothing for it. The risk factors repeat the disclosure and add that the litigation "has resulted in additional costs."

The product and the FDA

The iLet was cleared by the FDA in May 2023 for type 1 diabetes in adults and children six years of age and older, and U.S. commercialization began that month. In September 2026 the company received FDA clearance for Mint, its patch pump, and has not yet started commercial sales of it. The company also names the bihormonal iLet, which uses insulin and glucagon, and an iLet for type 2 diabetes as future products that would need FDA authorization.

The 10-Q also refers to a Form 483 and a Warning Letter. Beta Bionics reports quality system remediation expenses that began in the fourth quarter of 2025 and continued through 2026, including contractor support and updates to its quality system "to meet FDA expectations." The filing does not describe the observations in either document.

Growth, losses and the September offering

Net sales were $35,505 thousand in the third quarter, against $27,253 thousand a year earlier, and $95,144 thousand for nine months. Sales and marketing expenses were $70,499 thousand for nine months, and the company reports a net loss of $69,651 thousand for that period, against $59,734 thousand a year earlier. It expects to incur significant operating losses for the foreseeable future as it commercializes Mint. Operating activities used $50,741 thousand in cash in the nine months.

In September 2026 the company completed a follow-on public offering of common stock and a pre-funded warrant. It issued 8,956,523 shares in the offering and received net proceeds of approximately $161.3 million after underwriting discounts, commissions and offering expenses of $11.2 million. The 10-Q does not name the underwriters. Net cash provided by financing activities was $166.0 million for the nine months. At September 30, 2026 Beta Bionics had cash, cash equivalents and short-term and long-term investments of $373.6 million, and 54,362,972 shares of common stock outstanding on the balance sheet date.

The company says that cash, together with its recent offerings, should fund operating expenses and capital expenditures for the foreseeable future, and adds that the estimate rests on assumptions that may prove wrong. The filing sets no date for any ruling or schedule in the Holtzman case.

Report an error

Companies in this story

BBNXBeta Bionics, Inc.NASDAQ · United StatesOpen the starter desk